The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
Femke CrouwelAhmed B BayoumyChris J J MulderJob H C PetersPaul J BoekemaLuc J J DerijksSybrand Y de BoerPaul C van de MeebergIshfaq AhmadHans J C BuiterNanne K de BoerPublished in: Inflammatory bowel diseases (2023)
At 12 months, first-line thioguanine therapy was clinically effective in 53% of thiopurine-naïve inflammatory bowel disease patients with an acceptable safety profile.